Galmed Pharmaceuticals
GLMD • NASDAQ
Galmed Pharmaceuticals is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Allen Baharaff, with a market cap of $3.3M.
CEOAllen Baharaff
Next Earnings
Upcoming earnings announcement for Galmed Pharmaceuticals
Date
Wednesday, April 1, 2026 (in 2 months)
Timing
Before Market Open (3:00 AM New York)
Fiscal Period
Q4 2025
EPS Estimate
-$0.51
Earnings History
Past 12 earnings reports for Galmed Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 26, 2025 | Q3 2025 | -$0.33Est: -$0.54 | +38.9% | - | — | — |
| Aug 28, 2025 | Q2 2025 | -$0.63Est: -$0.79 | +20.3% | - | — | — |
| May 22, 2025 | Q1 2025 | -$0.62 | — | - | — | — |
| Nov 14, 2024 | Q3 2024 | -$2.31 | — | - | — | — |
| Aug 28, 2024 | Q2 2024 | -$2.16 | — | - | — | — |
| May 30, 2024 | Q1 2024 | -$2.76 | — | - | — | — |
| Apr 4, 2024 | Q4 2023 | -$11.76Est: -$3.84 | -206.3% | - | — | — |
| Nov 22, 2023 | Q3 2023 | -$2.88Est: -$3.60 | +20.0% | - | — | — |
| Aug 9, 2023 | Q2 2023 | -$11.40Est: -$4.08 | -179.4% | - | — | — |
| Jun 1, 2023 | Q1 2023 | -$13.08Est: -$18.00 | +27.3% | - | — | — |
| Mar 29, 2023 | Q4 2022 | -$18.00Est: -$25.20 | +28.6% | - | — | — |
| Nov 16, 2022 | Q3 2022 | -$37.80Est: -$28.80 | -31.2% | - | — | — |